课题基金 / 基金详情

GENETIC ANALYSIS OF MYCOLIC ACID SYNTHESIS

GENETIC ANALYSIS OF MYCOLIC ACID SYNTHESIS
霉菌酸合成的遗传分析
批准号:
6235352
负责人:
John T Belisle
金额:
$12.66万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1997
资助国家:
美国
项目状态:
已结题
起止时间:
1997-08-01 至 1998-07-31

项目摘要

项目成果

John T Belisle的其他基金

相似基金

相关文献

中文摘要
翻译
分枝杆菌细胞壁的独特结构是由于这一新颖的 共价结合的真菌酸的排列及其性质 阿拉伯半乳糖-肽多聚糖复合体。毫无疑问,生物合成的 这种细胞壁基质的生物合成途径将高度涉及 特殊的酶和酶复合体可被开发用于 抗分枝杆菌新药的开发。发展的迫切需要 控制结核病的新的和更有效的化疗药物已经 导致我们目前在定义关键细胞壁的生物合成方面所做的努力 产品。合理药物设计最有特色的目标之一 抗结核和非典型分枝杆菌病是细胞壁 霉酚酸酯-α-烷基,β-羟基长链(C80)脂肪酸。这个 对它们的生物合成的研究,可能涉及到特殊的伸长, Claisen冷凝和“运输机”(项目1)将得到补充 通过基因鉴定、同源突变体的产生和提供 用于合成孔径雷达研究的重组酶。根据我们的主要观察, 初级真菌转移酶是众所周知的抗原85,α-抗原。 因此,编码关键靶标的基因是已知的,并且已经成熟 构建“基因敲除”突变体。Fas-I和Fas-I最近的可用性 -II酶,允许它们的基因通过反向遗传学和 也是被操纵的。已经重组的结核分枝杆菌已经被 在耻垢分枝杆菌中的表达为基因定义提供了一种现成的手段 F是结核杆菌最具特征的表型,也是 有效药物的所在地,在我们的工业合作伙伴眼中, 新药开发的首要重点。
英文摘要
The unique architecture of the mycobacterial cell wall is due to the novel arrangement of the covalently bound mycolic acids and the characteristic arabinogalactan-peptidoglycan complex. Undoubtedly, the biosynthetic pathways for the biosynthesis of this cell wall matrix will involve highly specialized enzymes and enzyme complexes that may be exploited for the development of new anti-mycobacterial drugs. The urgent need to develop new and more effective chemotherapeutic agents to control tuberculosis has lead to our current endeavors in defining the biosynthesis of key cell wall products. Among the most distinctive targets for rational drug design against tuberculosis and atypical mycobacterioses are the cell wall mycolates - alpha-alkyl, beta-hydroxy long chain (C80) fatty acids. The study of their biosynthesis, presumably involving specialized elongation, Claisen condensation and "transporters; (Project 1), will be complemented by identification of genes, generation of isogeneic mutants, and provision of recombinant enzymes for SAR studies. With our key observation that a primary mycolyltransferase is the well known antigen 85, alpha-antigen complex, the genes encoding a key target are thus known and are ripe for construction of "knock-out" mutants. The recent availability of FAS-I and -II enzymes, allows for their genes to be located by reverse genetics and also manipulated. Already recombinant M. tuberculosis mycolates have been expressed in M. smegmatis providing a ready means for genetic definition f the most characteristic phenotype of the tubercle bacillus, and also the site of effective drugs, and, in the eyes of our industrial partners, a prime focus for new drug development.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Evaluation of new diagnostics for incident, active and recurrent TB (ENDx-Tb)
  • 批准号:
    10197000
  • 项目类别:
  • 资助金额:
    $150.0万
  • 财政年份:
    2020
  • 负责人:
    John T Belisle
  • 依托单位:
Evaluation of new diagnostics for incident, active and recurrent TB (ENDx-Tb)
  • 批准号:
    10418673
  • 项目类别:
  • 资助金额:
    $150.0万
  • 财政年份:
    2020
  • 负责人:
    John T Belisle
  • 依托单位:
Evaluation of new diagnostics for incident, active and recurrent TB (ENDx-Tb)
  • 批准号:
    9981167
  • 项目类别:
  • 资助金额:
    $150.0万
  • 财政年份:
    2020
  • 负责人:
    John T Belisle
  • 依托单位:
Host Metabolic Biosignatures for the Diagnosis of Lyme Disease
  • 批准号:
    10409724
  • 项目类别:
  • 资助金额:
    $75.23万
  • 财政年份:
    2019
  • 负责人:
    John T Belisle
  • 依托单位:
海外基金